{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:21:19Z","timestamp":1773231679280,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.thromres.2023.06.021","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T12:10:03Z","timestamp":1687608603000},"page":"46-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors"],"prefix":"10.1016","volume":"229","author":[{"given":"Gregory","family":"Pon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Pelsue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujan Teegala","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushik","family":"Parsha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Gulbis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean I.","family":"Savitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa A.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2023.06.021_bb0005","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0010","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0015","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0020","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0025","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet."},{"key":"10.1016\/j.thromres.2023.06.021_bb0035","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1212\/WNL.0000000000003886","article-title":"Outcome of intracerebral hemorrhage associated with different oral anticoagulants","volume":"88","author":"Wilson","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2023.06.021_bb0040","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.thromres.2023.06.021_bb0045","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.025","article-title":"Intracerebral hemorrhagic expansion occurs in patients using non\u2013vitamin K antagonist oral anticoagulants comparable with patients using warfarin","volume":"26","author":"Melmed","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.thromres.2023.06.021_bb0050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1001\/jama.2017.21917","article-title":"Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality","volume":"319","author":"Inohara","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2023.06.021_bb0055","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1212\/WNL.0000000000002310","article-title":"Volume and function outcome of intracerebral hemorrhage according to oral anticoagulation type","volume":"86","author":"Wilson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2023.06.021_bb0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000346599","article-title":"Hematoma expansion following acute intracerebral hemorrhage","volume":"35","author":"Brouwers","year":"2013","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.thromres.2023.06.021_bb0065","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1212\/WNL.0b013e3182143317","article-title":"Defining hematoma expansion in intracerebral hemorrhage; relationship with patient outcomes","volume":"76","author":"Dowlatshahi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2023.06.021_bb0070","series-title":"Kcentra [Package Insert]","year":"2014"},{"key":"10.1016\/j.thromres.2023.06.021_bb0075","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2023.06.021_bb0080","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1080\/02688690050175265","article-title":"Prothrombin complex concentrate for oral anticoagulation reversal in neurosurgical emergencies","volume":"14","author":"Cartmill","year":"2000","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.thromres.2023.06.021_bb0085","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12028-015-0222-x","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine","volume":"24","author":"Frontera","year":"2016","journal-title":"Neurocrit. Care."},{"issue":"Suppl","key":"10.1016\/j.thromres.2023.06.021_bb0090","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2023.06.021_bb0095","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.06.021_bb0100","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.06.021_bb0105","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0885066618800657","article-title":"Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients","volume":"35","author":"Allison","year":"2020","journal-title":"J. Intensive Care Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11239-019-01846-5","article-title":"Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor xa inhibitor-related bleeding: a retrospective study","volume":"48","author":"Smith","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2023.06.021_bb0115","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa inhibitor-related intracranial hemorrhage: results from a multicenter, observational cohort receiving prothrombin complex concentrates","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2023.06.021_bb0120","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.25134","volume":"83","author":"Gerner","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.thromres.2023.06.021_bb0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11739-018-1977-9","article-title":"Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate","volume":"14","author":"Sheikh-Taha","year":"2019","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/trf.13406","article-title":"Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin k antagonist reversal in a real-world setting","volume":"56","author":"Joseph","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.thromres.2023.06.021_bb0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2007.01594.x","article-title":"Factor VIII inhibitor bypassing activity (FEIBA) \u2013 addressing safety issues","volume":"14","author":"Aledort","year":"2008","journal-title":"Haemophilia."},{"key":"10.1016\/j.thromres.2023.06.021_bb0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/08998280.2018.1440858","article-title":"Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibiotrs versus vitamin k antagonists treated with 4-factor prothrombin complex concentration","volume":"31","author":"Harrison","year":"2018","journal-title":"Proc. (Baylor Univ. Med. Cent.)"},{"key":"10.1016\/j.thromres.2023.06.021_bb0145","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11239-021-02613-1","article-title":"Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage","volume":"54","author":"Pasciolla","year":"2022","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.thromres.2023.06.021_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ajem.2022.04.044","article-title":"Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin","volume":"57","author":"Heath","year":"2022","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.thromres.2023.06.021_bb0155","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/01.STR.32.4.891","article-title":"The ICH score: a simple, reliable grading scale for intracerebral hemorrhage","volume":"32","author":"Hemphill","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2023.06.021_bb0160","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1212\/WNL.0000000000004255","article-title":"Assessment of the interaction of age and sex on 90-day outcome after intracerebral hemorrhage","volume":"89","author":"James","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2023.06.021_bb0165","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/01.wnl.0000179178.37713.69","article-title":"Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage","volume":"65","author":"Toyoda","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2023.06.021_bb0170","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/01.STR.24.7.987","article-title":"Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor or 30-day mortality","volume":"24","author":"Broderick","year":"1993","journal-title":"Stroke"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823001937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:51:03Z","timestamp":1758736263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823001937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":34,"alternative-id":["S0049384823001937"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.06.021","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}